Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

CSL to pay $355M upfront to co-develop Alentis’ kidney and liver drug

The Australian drugmaker CSL will pay $355 million for Alentis Therapeutics’ anti-fibrosis drug, plus as much as $1.2 billion in future payments. Under the deal announced Sunday evening, CSL will co-develop ...

We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.

Read the original at endpoints.news →

More in Health & Medicine

The mental scars of climate disasters

COP31 is just over a month away, and protecting people from flooding and other weather disasters is high on the agenda. Health Beat looks at how weather affects our state of mind — and why it matters.

BHEKISISA CROSSWORD #18

From health policy to the people behind the stories, our crossword takes you through Bhekisisa’s archive one clue at a time. How many can you solve without looking up the answers?

More from Monday 5 October →